151 related articles for article (PubMed ID: 37810973)
21. Efficacy and safety of irinotecan combined with raltitrexed or irinotecan monotherapy for salvage chemotherapy of esophageal squamous cell cancer: A prospective, open label, randomized phase II study.
Dai X; Tao L; Wang J; Wu W; Bian W; Dai X; Chen S
Cancer Med; 2023 Aug; 12(15):16108-16118. PubMed ID: 37325938
[TBL] [Abstract][Full Text] [Related]
22. Exploration on the first-line treatment of ERBB2-altered advanced non-small cell lung cancer: A multicenter retrospective study.
Chen J; Xu C; Wang Q; Lv J; Lu W; Zhang Y; Yao Y; Gu X; Wu G; Hao Y; Pan W; Wang W; Zhang S; Lv T; Song Y; Wang D
Lung Cancer; 2023 Sep; 183():107315. PubMed ID: 37517117
[TBL] [Abstract][Full Text] [Related]
23. A real-world study of anlotinib combined with GS regimen as first-line treatment for advanced pancreatic cancer.
Zhan G; Hu J; Da S; Weng J; Zhou C; Wen F; Liu S; Fang F; Shen E; Zhou Q; Luo P; Xu M; Zhan D; Su Y
Front Endocrinol (Lausanne); 2023; 14():1110624. PubMed ID: 36742383
[TBL] [Abstract][Full Text] [Related]
24. Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies.
Stouvenot M; Meurisse A; Saint A; Buecher B; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Smith D; Ghiringhelli F; Parzy A; de la Fouchardiere C; Almotlak H; Vienot A; Jacquin M; Taieb J; Nguyen T; Vernerey D; Borg C; Kim S
Eur J Cancer; 2022 Feb; 162():138-147. PubMed ID: 34995900
[TBL] [Abstract][Full Text] [Related]
25. [Comparison of Efficacy and Safety of Different Therapeutic Regimens as
Second-line Treatment for Small Cell Lung Cancer].
Li Z; Liu X; Li J; Gao H; Tang C; Li X; Guo W; Qin H; Wang W; Qu L; Chen J
Zhongguo Fei Ai Za Zhi; 2015 May; 18(5):280-8. PubMed ID: 25975298
[TBL] [Abstract][Full Text] [Related]
26. PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: A real-world retrospective cohort study.
Chen S; Wei H; Zhao W; Jiang W; Ning R; Zhou S; Tan L; Wang H; Su C; He J; Zeng A; Zhao Y; Yu Q
Front Immunol; 2022; 13():1059995. PubMed ID: 36569915
[TBL] [Abstract][Full Text] [Related]
27. Effect of cetuximab combined with chemotherapy in treating metastatic colorectal cancer and its prognostic analysis.
Wu J; Wang Z; Jin C; Ren H; Hu Y; Yang B; Hu Y
J BUON; 2021; 26(1):101-108. PubMed ID: 33721439
[TBL] [Abstract][Full Text] [Related]
28. Assessing treatment outcomes of chemoimmunotherapy in extensive-stage small cell lung cancer: an integrated clinical and radiomics approach.
Zhao J; He Y; Yang X; Tian P; Zeng L; Huang K; Zhao J; Zhou J; Zhu Y; Wang Q; Chen M; Li W; Gao Y; Zhang Y; Xia Y
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730276
[TBL] [Abstract][Full Text] [Related]
29. Multimodal treatment for local recurrent malignant gliomas: Resurgery and/or reirradiation followed by chemotherapy.
Prelaj A; Rebuzzi SE; Grassi M; Giròn Berrìos JR; Pecorari S; Fusto C; Ferrara C; Salvati M; Stati V; Tomao S; Bianco V
Mol Clin Oncol; 2019 Jan; 10(1):49-57. PubMed ID: 30655977
[TBL] [Abstract][Full Text] [Related]
30. Tailoring second-line or above therapy for patients with advanced or metastatic gastric cancer: A multicenter real-world study.
Nie C; Xu W; Lv H; Gao X; Li G; Chen B; Wang J; Liu Y; Zhao J; He Y; Wang S; Chen X
Front Pharmacol; 2022; 13():1043217. PubMed ID: 36467052
[No Abstract] [Full Text] [Related]
31. Apatinib in Combination with S-1 as First-Line Treatment in Patients with Advanced Metastatic Gastric Cancer: Results from an Open, Exploratory, Single-Arm, Phase II Trial.
Zhou N; Zhang C; Liu D; Liu K; Wang G; Zhu H; Zhang J; Jiang M; Liu N; Zhang X
Oncologist; 2021 Mar; 26(3):e374-e381. PubMed ID: 33244809
[TBL] [Abstract][Full Text] [Related]
32. Patterns of Chemotherapy Use in a U.S.-Based Cohort of Patients with Metastatic Pancreatic Cancer.
Abrams TA; Meyer G; Meyerhardt JA; Wolpin BM; Schrag D; Fuchs CS
Oncologist; 2017 Aug; 22(8):925-933. PubMed ID: 28476943
[TBL] [Abstract][Full Text] [Related]
33. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens.
Wainberg ZA; Feeney K; Lee MA; Muñoz A; Gracián AC; Lonardi S; Ryoo BY; Hung A; Lin Y; Bendell J; Hecht JR
BMC Cancer; 2020 Jul; 20(1):633. PubMed ID: 32641104
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of continuous infusion of Rh-endostatin combined with platinum-based chemotherapy for advanced triple-negative breast cancer.
Tan A; Wang H; Nong L; Jia Y; Liu Y; Zhong W; Qin F; Wang H; Tang J; Zhou W; Lu Y; Xie W
Ann Palliat Med; 2021 Dec; 10(12):12101-12112. PubMed ID: 35016411
[TBL] [Abstract][Full Text] [Related]
35. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
[TBL] [Abstract][Full Text] [Related]
36. [Efficacy and prognostic factors of 178 advanced non-small lung cancer patients undergoing different second-line chemotherapeutic regimens].
Kong Q; Wang XY; Jiang RC; Ba Y; Li K
Zhonghua Zhong Liu Za Zhi; 2016 Apr; 38(4):294-9. PubMed ID: 27087377
[TBL] [Abstract][Full Text] [Related]
37. Pazopanib in Metastatic Renal Cancer: A "Real-World" Experience at National Cancer Institute "Fondazione G. Pascale".
Cecere SC; Rossetti S; Cavaliere C; Della Pepa C; Di Napoli M; Crispo A; Iovane G; Piscitelli R; Sorrentino D; Ciliberto G; Maiolino P; Muto P; Perdonà S; Berretta M; Pignata S; Facchini G; D'Aniello C
Front Pharmacol; 2016; 7():287. PubMed ID: 27630568
[TBL] [Abstract][Full Text] [Related]
38. Hepatic arterial infusion chemotherapy combined with anti-PD-1/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study.
Zhang W; Zhang K; Liu C; Gao W; Si T; Zou Q; Guo Z; Yang X; Li M; Liu D; Mu H; Li H; Yu H; Xing W
Front Immunol; 2023; 14():1127349. PubMed ID: 37180098
[TBL] [Abstract][Full Text] [Related]
39. The Relationship Between Short-Term Surrogate Endpoint Indicators and mPFS and mOS in Clinical Trials of Malignant Tumors: A Case Study of Approved Molecular Targeted Drugs for Non-Small-Cell Lung Cancer in China.
Rui M; Wang Z; Fei Z; Wu Y; Wang Y; Sun L; Shang Y; Li H
Front Pharmacol; 2022; 13():862640. PubMed ID: 35370659
[No Abstract] [Full Text] [Related]
40. Rechallenge of immunotherapy beyond progression in patients with extensive-stage small-cell lung cancer.
Li L; Liu T; Liu Q; Mu S; Tao H; Yang X; Li Y; Xiong Q; Wang L; Hu Y
Front Pharmacol; 2022; 13():967559. PubMed ID: 36147357
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
